Study Name Principal Investigator
A011106; ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study Ghamande, Sharad
A011502: A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial Ghamande, Sharad
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009) (MK7339-009) Krutchik, Allan
Breast and Ovarian Cancer in African American Women: Intergenerational Cancer Prevention Vernon, Marlo
CT7001: A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies Krutchik, Allan
Development of a patient centered primary and secondary prevention intervention for breast and ovarian cancer in African American women Vernon, Marlo
Developmental Gene Discovery Project: Mapping and Identifying New Genes in Uterine and Vaginal Development; Identifying New Genes Causing Birth Defects in Children Layman, Lawrence
EA1131 A Randomized Phase III Post Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy Ghamande, Sharad
Genetics of Delayed Puberty/ Genes Important in Puberty, Genetics of Infertility and Medical Illness Layman, Lawrence
MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types Ghamande, Sharad
ONT-380-206: Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma Ghamande, Sharad
SGNTUC-016: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02) Raval, Priyanka
TAEK-VAC-HerBy-001: Phase 1 trial of intravenous administration of TAEK-VAC-HerBy vaccine alone and in combination with HER2-antibodies in patients with advanced cancer Raval, Priyanka
Understanding the Genetic Basis of Transgender Identity Layman, Lawrence
RESEARCH. INNOVATION. DISCOVERY.